Literature DB >> 24614078

Influence of pre-existing hemagglutination inhibition titers against historical influenza strains on antibody response to inactivated trivalent influenza vaccine in adults 50-80 years of age.

Ted M Ross1, Chyongchiou Jeng Lin2, Mary Patricia Nowalk2, Hsin-Hui Huang2, Sarah M Spencer3, David K Shay3, Suryaprakash Sambhara3, Maria E Sundaram4, Thomas Friedrich5, Sandy Sauereisen6, Chalise E Bloom1, Richard K Zimmerman2.   

Abstract

BACKGROUND: Concerns about influenza vaccine effectiveness in older adults and the role of influenza strains encountered earlier in life led to this study.
METHODS: Antibody responses against antigens in the 2011-2012 influenza vaccine at 21 days post vaccination were analyzed in 264 individuals aged 50-80 years. At Days 0 and 21, sera were tested for hemagglutination-inhibition titers against these vaccine strains and at Day 0 against a panel of 15 historical seasonal strains.:
RESULTS: The proportions of participants with seroprotective titers ≥1:40 to the vaccine strains at Days 0 and 21, respectively, were 37% and 66% for A(H1N1) and 28% and 63% for A(H3N2). An increasing number of responses ≥1:40 against historical strains was associated with seroprotective responses after vaccination among participants with a titer<1:40 at Day 0 for A(H1N1) and A(H3N2) vaccine strains (P<0.01). In multivariable regression analyses among those with Day 0 titer<1:40, after controlling for age, sex, race, site and diabetes, Day 21 titers ≥ 1:40 for the vaccine A strains were significantly more likely as the number of seroprotective responses against historical strains increased (A(H1N1) odds ratio [OR] = 1.41, 95% confidence interval [CI] = 1.09-1.82 and A(H3N2) OR = 1.32, 95% CI = 1.07-1.62). The likelihood of seroconversion was significantly higher with an increasing number of responses to historical strains for A(H3N2) only (OR = 1.24, 95% CI = 1.01-1.52). Seroconversion was significantly less likely as Day 0 vaccine strain titers increased.
CONCLUSIONS: Seroprotective titers after influenza vaccination increased as the number of responses to historical strains increased.

Entities:  

Keywords:  Human influenza; antibodies; immune response; immunogenicity

Mesh:

Substances:

Year:  2014        PMID: 24614078      PMCID: PMC4896607          DOI: 10.4161/hv.28313

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   3.452


  29 in total

Review 1.  Immunity to influenza in the elderly.

Authors:  R G Webster
Journal:  Vaccine       Date:  2000-02-25       Impact factor: 3.641

2.  C3d enhancement of antibodies to hemagglutinin accelerates protection against influenza virus challenge.

Authors:  T M Ross; Y Xu; R A Bright; H L Robinson
Journal:  Nat Immunol       Date:  2000-08       Impact factor: 25.606

3.  Long-term immunogenicity of influenza vaccine among the elderly: Risk factors for poor immune response and persistence.

Authors:  Joon Young Song; Hee Jin Cheong; In Sook Hwang; Won Suk Choi; Yu Mi Jo; Dae Won Park; Geum Joo Cho; Taik Gun Hwang; Woo Joo Kim
Journal:  Vaccine       Date:  2010-04-13       Impact factor: 3.641

4.  Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2011.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2011-08-26       Impact factor: 17.586

5.  Pandemic H1N1 influenza vaccine induces a recall response in humans that favors broadly cross-reactive memory B cells.

Authors:  Gui-Mei Li; Christopher Chiu; Jens Wrammert; Megan McCausland; Sarah F Andrews; Nai-Ying Zheng; Jane-Hwei Lee; Min Huang; Xinyan Qu; Srilatha Edupuganti; Mark Mulligan; Suman R Das; Jonathan W Yewdell; Aneesh K Mehta; Patrick C Wilson; Rafi Ahmed
Journal:  Proc Natl Acad Sci U S A       Date:  2012-05-21       Impact factor: 11.205

6.  Estimates of deaths associated with seasonal influenza --- United States, 1976-2007.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2010-08-27       Impact factor: 17.586

7.  Induction of heterosubtypic immunity to influenza A virus using a DNA vaccine expressing hemagglutinin-C3d fusion proteins.

Authors:  Judy A Mitchell; Thomas D Green; Rick A Bright; Ted M Ross
Journal:  Vaccine       Date:  2003-02-14       Impact factor: 3.641

8.  Influenza-associated hospitalizations in the United States.

Authors:  William W Thompson; David K Shay; Eric Weintraub; Lynnette Brammer; Carolyn B Bridges; Nancy J Cox; Keiji Fukuda
Journal:  JAMA       Date:  2004-09-15       Impact factor: 56.272

9.  Evidence for antigenic seniority in influenza A (H3N2) antibody responses in southern China.

Authors:  Justin Lessler; Steven Riley; Jonathan M Read; Shuying Wang; Huachen Zhu; Gavin J D Smith; Yi Guan; Chao Qiang Jiang; Derek A T Cummings
Journal:  PLoS Pathog       Date:  2012-07-19       Impact factor: 6.823

10.  Re-engaging cross-reactive memory B cells: the influenza puzzle.

Authors:  Ali H Ellebedy; Rafi Ahmed
Journal:  Front Immunol       Date:  2012-03-30       Impact factor: 7.561

View more
  12 in total

1.  Design and Characterization of a Computationally Optimized Broadly Reactive Hemagglutinin Vaccine for H1N1 Influenza Viruses.

Authors:  Donald M Carter; Christopher A Darby; Bradford C Lefoley; Corey J Crevar; Timothy Alefantis; Raymond Oomen; Stephen F Anderson; Tod Strugnell; Guadalupe Cortés-Garcia; Thorsten U Vogel; Mark Parrington; Harold Kleanthous; Ted M Ross
Journal:  J Virol       Date:  2016-04-14       Impact factor: 5.103

2.  Influence of Birth Cohort on Effectiveness of 2015-2016 Influenza Vaccine Against Medically Attended Illness Due to 2009 Pandemic Influenza A(H1N1) Virus in the United States.

Authors:  Brendan Flannery; Catherine Smith; Rebecca J Garten; Min Z Levine; Jessie R Chung; Michael L Jackson; Lisa A Jackson; Arnold S Monto; Emily T Martin; Edward A Belongia; Huong Q McLean; Manjusha Gaglani; Kempapura Murthy; Richard Zimmerman; Mary Patricia Nowalk; Marie R Griffin; H Keipp Talbot; John J Treanor; David E Wentworth; Alicia M Fry
Journal:  J Infect Dis       Date:  2018-06-20       Impact factor: 5.226

3.  Immune history profoundly affects broadly protective B cell responses to influenza.

Authors:  Sarah F Andrews; Yunping Huang; Kaval Kaur; Lyubov I Popova; Irvin Y Ho; Noel T Pauli; Carole J Henry Dunand; William M Taylor; Samuel Lim; Min Huang; Xinyan Qu; Jane-Hwei Lee; Marlene Salgado-Ferrer; Florian Krammer; Peter Palese; Jens Wrammert; Rafi Ahmed; Patrick C Wilson
Journal:  Sci Transl Med       Date:  2015-12-02       Impact factor: 17.956

4.  An AGM model for changes in complement during pregnancy: neutralization of influenza virus by serum is diminished in late third trimester.

Authors:  Anne E Mayer; Griffith D Parks
Journal:  PLoS One       Date:  2014-11-19       Impact factor: 3.240

5.  Neutralizing Antibody Responses to Antigenically Drifted Influenza A(H3N2) Viruses among Children and Adolescents following 2014-2015 Inactivated and Live Attenuated Influenza Vaccination.

Authors:  Min Z Levine; Judith M Martin; F Liaini Gross; Stacie Jefferson; Kelly Stefano Cole; Crystal Ann Archibald; Mary Patricia Nowalk; Michael Susick; Krissy Moehling; Sarah Spencer; Jessie R Chung; Brendan Flannery; Richard K Zimmerman
Journal:  Clin Vaccine Immunol       Date:  2016-10-04

6.  Impact of age and pre-existing influenza immune responses in humans receiving split inactivated influenza vaccine on the induction of the breadth of antibodies to influenza A strains.

Authors:  Ivette A Nuñez; Michael A Carlock; James D Allen; Simon O Owino; Krissy K Moehling; Patricia Nowalk; Michael Susick; Kensington Diagle; Kristen Sweeney; Sophia Mundle; Thorsten U Vogel; Simon Delagrave; Moti Ramgopal; Richard K Zimmerman; Harry Kleanthous; Ted M Ross
Journal:  PLoS One       Date:  2017-11-01       Impact factor: 3.240

7.  Nine μg intradermal influenza vaccine and 15 μg intramuscular influenza vaccine induce similar cellular and humoral immune responses in adults.

Authors:  Nolwenn Nougarede; Hélène Bisceglia; Aurore Rozières; Catherine Goujon; Florence Boudet; Philippe Laurent; Beatrice Vanbervliet; Karen Rodet; Ana Hennino; Jean-François Nicolas
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

8.  A broadly neutralizing anti-influenza antibody reveals ongoing capacity of haemagglutinin-specific memory B cells to evolve.

Authors:  Ying Fu; Zhen Zhang; Jared Sheehan; Yuval Avnir; Callie Ridenour; Thomas Sachnik; Jiusong Sun; M Jaber Hossain; Li-Mei Chen; Quan Zhu; Ruben O Donis; Wayne A Marasco
Journal:  Nat Commun       Date:  2016-09-13       Impact factor: 14.919

Review 9.  Towards a universal influenza vaccine: different approaches for one goal.

Authors:  Giuseppe A Sautto; Greg A Kirchenbaum; Ted M Ross
Journal:  Virol J       Date:  2018-01-19       Impact factor: 4.099

10.  Baseline immune profile by CyTOF can predict response to an investigational adjuvanted vaccine in elderly adults.

Authors:  Christine M D Lingblom; Sangeeta Kowli; Nithya Swaminathan; Holden T Maecker; Stacie L Lambert
Journal:  J Transl Med       Date:  2018-06-05       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.